Patents by Inventor Richard Moxon
Richard Moxon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140050731Abstract: The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine including one or more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and methods of preventing and treating Neisseria infections. The immunogens are based on elements of the inner core lipopolysaccharide.Type: ApplicationFiled: August 13, 2013Publication date: February 20, 2014Applicant: Isis Innovation Ltd.Inventors: Joyce Susan Plested, Michael Paul Jennings, Margaret Ann Jaqueline Gidney, Andrew David Cox, James Clare Richards, Edward Richard Moxon
-
Publication number: 20130085262Abstract: The invention provides a novel surface polypeptide from Neisseria meningitidis as well as nucleic acid and nucleic acid sequence homologues encoding this protein. Pharmaceutical compositions containing the polypeptide and nucleic acids of the invention are also disclosed as well as methods useful in the treatment, prevention and diagnosis of N. meningitidis infection.Type: ApplicationFiled: September 14, 2011Publication date: April 4, 2013Applicant: The University of QueenslandInventors: Ian Richard Anselm PEAK, Michael Paul Jennings, E. Richard Moxon
-
Publication number: 20120123093Abstract: The invention provides a novel surface polypeptide from Neisseria meningitidis as well as nucleic acid and nucleic acid sequence homologues encoding this protein. Pharmaceutical compositions containing the polypeptide and nucleic acids of the invention are also disclosed as well as methods useful in the treatment, prevention and diagnosis of N. meningitidis infection.Type: ApplicationFiled: September 14, 2011Publication date: May 17, 2012Applicant: The University of QueenslandInventors: Ian Richard Anselm PEAK, Michael Paul Jennings, E. Richard Moxon
-
Patent number: 8148499Abstract: The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine comprising one or more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and methods of preventing and treating Neisseria infections. The immunogens are based on elements of the inner core lipopolysaccharide.Type: GrantFiled: February 14, 2011Date of Patent: April 3, 2012Assignee: Isis Innovation Ltd.Inventors: Joyce Susan Plested, Michael Paul Jennings, Margaret Ann Jaqueline Gidney, Andrew David Cox, James Clare Richards, Edward Richard Moxon
-
Patent number: 8067004Abstract: The invention provides a novel surface polypeptide from Neisseria meningitidis as well as nucleic acid and nucleic acid sequence homologues encoding this protein. Pharmaceutical compositions containing the polypeptide and nucleic acids of the invention are also disclosed as well as methods useful in the treatment, prevention and diagnosis of N. meningitidis infection.Type: GrantFiled: August 11, 2003Date of Patent: November 29, 2011Assignee: The University of QueenslandInventors: Ian Richard Anseim Peak, Michael Paul Jennings, E. Richard Moxon
-
Patent number: 8034358Abstract: The invention provides a novel surface polypeptide from Neisseria meningitidis as well as nucleic acid and nucleic acid sequence homologues encoding this protein. Pharmaceutical compositions containing the polypeptide and nucleic acids of the invention are also disclosed as well as methods useful in the treatment, prevention and diagnosis of N. meningitidis infection.Type: GrantFiled: July 12, 2007Date of Patent: October 11, 2011Assignee: The University of QueeslandInventors: Ian Richard Anselm Peak, Michael Paul Jennings, E. Richard Moxon
-
Publication number: 20110171234Abstract: The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine comprising o more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and m preventing and treating Neisseria infections.Type: ApplicationFiled: February 14, 2011Publication date: July 14, 2011Applicant: Isis Innovation LimitedInventors: Joyce Susan Plested, Michael Paul Jennings, Margaret Ann Jaqueline Gidney, Andrew David Cox, James Clare Richards, Edward Richard Moxon
-
Publication number: 20100331537Abstract: The invention provides a novel surface polypeptide from Neisseria meningitidis as well as nucleic acid and nucleic acid sequence homologues encoding this protein. Pharmaceutical compositions containing the polypeptide and nucleic acids of the invention are also disclosed as well as methods useful in the treatment, prevention and diagnosis of N. meningitidis infection.Type: ApplicationFiled: July 22, 2010Publication date: December 30, 2010Applicant: THE UNIVERSITY OF QUEENSLANDInventors: IAN RICHARD ANSELM PEAK, MICHAEL PAUL JENNINGS, E. RICHARD MOXON
-
Patent number: 7825225Abstract: The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine including one or more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and methods of preventing and treating Neisseria infections. The immunogens are based on elements of the inner core lipopolysaccharide.Type: GrantFiled: July 24, 2009Date of Patent: November 2, 2010Assignee: Isis Innovation Ltd.Inventors: Joyce Susan Plested, Michael Paul Jennings, Margaret Ann Jaqueline Gidney, Andrew David Cox, James Clare Richards, Edward Richard Moxon
-
Publication number: 20100015175Abstract: The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine including one or more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and methods of preventing and treating Neisseria infections. The immunogens are based on elements of the inner core lipopolysaccharide.Type: ApplicationFiled: July 24, 2009Publication date: January 21, 2010Applicant: Isis Innovation Ltd.Inventors: Joyce S. Plested, Michael P. Jennings, Margaret Anne Gidney, Andrew D. Cox, James C. Richards, E. Richard Moxon
-
Publication number: 20100016560Abstract: The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine including one or more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and methods of preventing and treating Neisseria infections. The immunogens are based on elements of the inner core lipopolysaccharide.Type: ApplicationFiled: July 24, 2009Publication date: January 21, 2010Applicant: Isis Innovation Ltd.Inventors: Joyce S. Plested, Michael P. Jennings, Margaret Ann J. Gidney, Andrew D. Cox, James C. Richards, E. Richard Moxon
-
Publication number: 20100010211Abstract: The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine including one or more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and methods of preventing and treating Neisseria infections. The immunogens are based on elements of the inner core lipopolysaccharide.Type: ApplicationFiled: July 24, 2009Publication date: January 14, 2010Applicant: Isis Innovation Ltd.Inventors: Joyce S. Plested, Michael P. Jennings, Margaret Anne Gidney, Andrew D. Cox, James C. Richards, E. Richard Moxon
-
Publication number: 20090270591Abstract: The invention provides a novel surface polypeptide from Neisseria meningitidis as well as nucleic acid and nucleic acid sequence homologues encoding this protein. Pharmaceutical compositions containing the polypeptide and nucleic acids of the invention are also disclosed as well as methods useful in the treatment, prevention and diagnosis of N. meningitidis infection.Type: ApplicationFiled: July 12, 2007Publication date: October 29, 2009Inventors: Ian Richard Anselm PEAK, Michael Paul Jennings, E. Richard Moxon
-
Patent number: 7364739Abstract: The present invention relates to a lipopolysaccharide moiety comprising a conserved triheptosyl inner-core moiety of lipopolysaccharide substantially free of variable outer core oligosaccharide chain extension, and to vaccines obtaines therefrom which are cross-reactive for Haemophilus influenzae strains. The invention also relates to defined mutations in the biosynthetic machinery for lipopolysaccharide (LPS;) expression in Haemophilus influenzae useful to obtain the abovementioned moiety. The invention also relates to using conjugates of the LPS from the mutant strains so obtained to elicit a heterologous immune response against a wide range of disease-causing H. influenzae strains. More specifically, the invention relates to vaccines for prevention of bacterial infections comprising core lipopolysaccharide of Haemophilus influenzae.Type: GrantFiled: August 27, 2001Date of Patent: April 29, 2008Assignees: National Research Council of Canada, The Chancellor, Masters, and Scholars of the University of OxfordInventors: James C. Richards, Andrew Cox, Richard Moxon, Derek Hood, Elke K. H. Schweda, Martin MÃ¥nsson
-
Publication number: 20050153057Abstract: The present invention relates to a lipopolysaccharide moiety comprising a conserved triheptosyl inner-core moiety of lipopolysaccharide substantially free of variable outer core oligosaccharide chain extension, and to vaccines obtaines therefrom which are cross-reactive for Haemophilus influenzae strains. The invention also relates to defined mutations in the biosynthetic machinery for lipopolysaccharide (LPS;) expression in Haemophilus influenzae useful to obtain the abovementioned moiety. The invention also relates to using conjugates of the LPS from the mutant strains so obtained to elicit a heterologous immune response against a wide range of disease-causing H. influenzae strains. More specifically, the invention relates to vaccines for prevention of bacterial infections comprising core lipopolysaccharide of Haemophilus influenzae.Type: ApplicationFiled: August 27, 2001Publication date: July 14, 2005Inventors: James Richards, Andrew Cox, Richard Moxon, Derek Hood, Elke Schweda, Martin Mansson
-
Publication number: 20050058660Abstract: The invention provides a novel surface polypeptide from Neisseria meningitidis as well as nucleic acid and nucleic acid sequence homologues encoding this protein. Pharmaceutical compositions containing the polypeptide and nucleic acids of the invention are also disclosed as well as methods useful in the treatment, prevention and diagnosis of N. meningitidis infection.Type: ApplicationFiled: August 11, 2003Publication date: March 17, 2005Inventors: Ian Richard Anselm Peak, Michael Paul Jennings, E. Richard Moxon
-
Patent number: 6607729Abstract: The invention provides a novel surface polypeptide from Neisseria meningitidis as well as nucleic acid and nucleic acid sequence homologues encoding this protein. Pharmaceutical compositions containing the polypeptide and nucleic acids of the invention are also disclosed as well as methods useful in the treatment, prevention and diagnosis of N. meningitidis infection.Type: GrantFiled: March 5, 2001Date of Patent: August 19, 2003Assignee: The University of QueenslandInventors: Ian Richard Anselm Peak, Michael Paul Jennings, E. Richard Moxon
-
Patent number: 6495345Abstract: The invention provides a novel surface polypeptide from Neisseria meningitidis as well as nucleic acid and nucleic acid sequence homologues encoding this protein. Pharmaceutical compositions containing the polypeptide and nucleic acids of the invention are also disclosed as well as methods useful in the treatment, prevention and diagnosis of N. meningitidis infection.Type: GrantFiled: September 26, 2000Date of Patent: December 17, 2002Assignee: The University of QueenslandInventors: Ian Richard Anselm Peak, Michael Paul Jennings, E. Richard Moxon
-
Publication number: 20020102276Abstract: The invention provides a novel surface polypeptide from Neisseria meningitidis as well as nucleic acid and nucleic acid sequence homologues encoding this protein. Pharmaceutical compositions containing the polypeptide and nucleic acids of the invention are also disclosed as well as methods useful in the treatment, prevention and diagnosis of N. meningitidis infection.Type: ApplicationFiled: March 5, 2001Publication date: August 1, 2002Inventors: Ian Richard Anselm Peak, Michael Paul Jennings, E. Richard Moxon
-
Patent number: 6210933Abstract: The structure and specificity of the recombinant &agr;-2,3-sialyltransferases from Neisseria spp, are disclosed. Their use in the production of desired carbohydrate structures is also provided.Type: GrantFiled: September 1, 1999Date of Patent: April 3, 2001Assignee: National Research Council of CanadaInventors: Michel Gilbert, Warren W. Wakarchuk, N. Martin Young, Michael P. Jennings, Edward Richard Moxon